[{"orgOrder":0,"company":"Organon","sponsor":"Dermavant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Organon","amount2":1.2,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":1.2,"dosageForm":"Cream","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Dermavant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Organon","amount2":1.2,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":1.2,"dosageForm":"Undisclosed","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Organon \/ Dar\u00e9 Bioscience","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Dar\u00e9 Bioscience"},{"orgOrder":0,"company":"Organon","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Licensing Agreement","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Organon","amount2":0.19,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.19,"dosageForm":"Gel","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Licensing Agreement","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Organon","amount2":0.19,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.19,"dosageForm":"Gel","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Licensing Agreement","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Organon","amount2":0.19,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.19,"dosageForm":"Gel","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Agreement","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Eli Lilly"},{"orgOrder":0,"company":"Organon","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Corifollitropin Alfa","moa":"Follicle stimulating hormone receptor","graph1":"Undisclosed","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.A.E","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Follitropin Beta","moa":"Follicle stimulating hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"6","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Perrigo Company plc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ IQVIA","highestDevelopmentStatusID":"11","companyTruncated":"Organon \/ IQVIA"},{"orgOrder":0,"company":"Organon","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"NETHERLANDS","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"FOR-6219","moa":"HSD17B1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Organon","amount2":0.94999999999999996,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.94999999999999996,"dosageForm":"Capsule","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"6","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"NETHERLANDS","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"FOR-6219","moa":"HSD17B1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Organon","amount2":0.94999999999999996,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.94999999999999996,"dosageForm":"Capsule","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"6","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Richmond Pharmacology","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"FOR-6219","moa":"HSD17B1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Organon \/ Richmond Pharmacology","highestDevelopmentStatusID":"6","companyTruncated":"Organon \/ Richmond Pharmacology"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"FOR-6219","moa":"HSD17B1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Hormone","year":"2022","type":"Acquisition","leadProduct":"Desogestrel","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Etonogestrel","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2021","type":"Demerger","leadProduct":"Etonogestrel","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2021","type":"Financing","leadProduct":"Etonogestrel","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Organon \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Merck & Co"},{"orgOrder":0,"company":"Organon","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Etonogestrel","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"6","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"IQVIA | OSTAtistics","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NOMAC-E2","moa":"Progesterone receptor\/Estrogen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Organon \/ IQVIA | OSTAtistics","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ IQVIA | OSTAtistics"},{"orgOrder":0,"company":"Organon","sponsor":"ObsEva","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Ebopiprant","moa":"prostaglandin receptor antagonists","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Organon","amount2":1,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":1,"dosageForm":"Undisclosed","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"8","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Licensing Agreement","leadProduct":"Pertuzumab","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase III","graph3":"Organon","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Samsung Bioepis","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Samsung Bioepis"},{"orgOrder":0,"company":"Organon","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"OG-6219","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"Organon \/ IQVIA"},{"orgOrder":0,"company":"Organon","sponsor":"Cirqle Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Organon","amount2":0.37,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.37,"dosageForm":"Gel","sponsorNew":"Organon \/ Cirqle Biomedical","highestDevelopmentStatusID":"4","companyTruncated":"Organon \/ Cirqle Biomedical"}]

Find Clinical Drug Pipeline Developments & Deals by Organon

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Bildyos (denosumab) is a biosimilar antibody candidate, which is approved for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

                          Product Name : Bildyos

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          September 02, 2025

                          Lead Product(s) : Denosumab

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Recipient : Shanghai Henlius Biotech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Through this acquisition, Organon enhances and broadens its U.S. biosimilars portfolio, gaining commercial rights in the US for tofidence (tocilizumab), an intravenous biosimilar to actemra.

                          Product Name : Tofidence

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Undisclosed

                          April 01, 2025

                          Lead Product(s) : Tocilizumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved FDF

                          Recipient : Biogen

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          03

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Etonogestrel is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Menstruation Disturbances.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          January 15, 2025

                          Lead Product(s) : Etonogestrel

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase I

                          Recipient : Maíta Poli de Araújo

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Vtama (tapinarof) cream is an aryl hydrocarbon receptor agonist steroid-free, topical cream, for the treatment of atopic dermatitis in adults & children 2 years of age & above.

                          Product Name : Vtama

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 16, 2024

                          Lead Product(s) : Tapinarof

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Vtama (tapinarof) cream is an aryl hydrocarbon receptor agonist steroid-free, topical cream, for the treatment of atopic dermatitis in adults & children 2 years of age & above.

                          Product Name : Vtama

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 05, 2024

                          Lead Product(s) : Tapinarof

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Through the acquisition, Organon will leverage the Dermavant pipeline, which includes Vtama (tapinarof) cream. It is indicated for the treatment of f plaque psoriasis in adults.

                          Product Name : Vtama

                          Product Type : Miscellaneous

                          Upfront Cash : $175.0 million

                          October 28, 2024

                          Lead Product(s) : Tapinarof

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Recipient : Dermavant Sciences

                          Deal Size : $1,200.0 million

                          Deal Type : Acquisition

                          blank

                          07

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Through the acquisition, Organon will leverage the Dermavant pipeline, which includes Vtama (tapinarof) cream. It is indicated for the treatment of f plaque psoriasis in adults.

                          Product Name : Vtama

                          Product Type : Miscellaneous

                          Upfront Cash : $175.0 million

                          September 18, 2024

                          Lead Product(s) : Tapinarof

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Recipient : Dermavant Sciences

                          Deal Size : $1,200.0 million

                          Deal Type : Acquisition

                          blank

                          08

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Organon expanded its agreement with Eli Lilly to become the sole distributor and promoter of Emgality (galcanezumab), which is indicated for the treatment of migraine.

                          Product Name : Emgality

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : $22.5 million

                          August 20, 2024

                          Lead Product(s) : Galcanezumab

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Recipient : Eli Lilly

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          09

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : HLX14 (denosumab-biosimilar) is a fully human recombinant anti-RANKL monoclonal antibody, which is approved for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          May 24, 2024

                          Lead Product(s) : Denosumab

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Recipient : Shanghai Henlius Biotech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Xaciato (clindamycin phosphate) vaginal gel 2% is a USFDA approved medication for the treatment of bacterial vaginosis (BV) in females 12 years of age and older.

                          Product Name : Xaciato

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          January 10, 2024

                          Lead Product(s) : Clindamycin Phosphate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Daré Bioscience

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank